SCHEMBL1940231

SCHEMBL1940231

Nc1ncnc2c1c(Cc1cccc(NS(=O)(=O)c3ccccc3Cl)c1)cn2C1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.52
ERBB2 P04626 6/20 0.52
ERBB3 P21860 6/20 0.52
ERBB4 Q15303 6/20 0.52
TEK Q02763 6/20 0.52
SRC P12931 7/20 0.50
IGF1R P08069 4/20 0.44
ABL1 P00519 4/20 0.43
ABL2 P42684 3/20 0.43
KDR P35968 4/20 0.42
EIF2AK3 Q9NZJ5 1/20 0.41
LCK P06239 3/20 0.41
RET P07949 3/20 0.41
CSF1R P07333 2/20 0.41
FGFR1 P11362 2/20 0.41
FLT1 P17948 2/20 0.41
FLT3 P36888 2/20 0.41
MST1R Q04912 2/20 0.41
NTRK3 Q16288 2/20 0.41
NTRK2 Q16620 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1940679 0.94 EGFR (0.51) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1941420 0.91 EGFR (0.53) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1941137 0.90 EGFR (0.60) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1941384 0.86 EGFR (0.56) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1940439 0.85 EGFR (0.70) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1939641 0.83 EGFR (0.75) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1939955 0.82 EGFR (0.53) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1941844 0.79 EGFR (0.72) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1940715 0.78 EGFR (0.74) EGFRERBB2ERBB3ERBB4TEK
SCHEMBL1939978 0.78 SRC (0.54) EGFRTEKSRCIGF1RABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP disclosed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US disclosed
CN-1726218-A Pyrrolopyrimidine derivatives PFIZER PROD INC (US) 2006-01-25 CN disclosed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037999-A1 Pyrrolopyrimidine derivatives CCNA1, CCNT1, TP53 EGFR 2758/4885ERBB2 2738/4885ERBB3 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.